Integrated CKD Focus Leverage the merged Akebia platform to position offerings for chronic kidney disease patients, highlighting continuity from Keryx’s portfolio (notably phosphate binders) and the combined company’s broader CKD pipeline.

Iron Management Opportunity Target nephrology and hospital systems with Auryxia and related iron management therapies, emphasizing the product’s role in treating iron deficiency anemia in CKD and potential cross-selling with hyperphosphatemia treatments.

Hyperphosphatemia Portfolio Promote Zerenex as a key iron-based phosphate binder for ESRD patients, identifying dialysis centers and nephrology clinics as primary sales targets with potential expansion into hospital formulary discussions.

FDA Milestones & Commercialization Capitalize on past FDA approvals and commercial launches to approach payer relations teams, outlining evidence of safety/efficacy, market uptake, and reimbursement pathways to support market access for CKD therapies.

Strategic Partnerships Explore collaborations with NKF-aligned programs and health systems, using the merger history to propose joint education, access initiatives, and outcomes-driven programs that enhance adoption of CKD-related medicines.